FDA puts hold on clinical trials for CAR-T cell therapy – BSA bureau (press release)
|
FDA puts hold on clinical trials for CAR–T cell therapy
BSA bureau (press release) Juno attributed the deaths to the interaction between the pre-conditioning chemo regimen —consisting of fludarabine and cyclophosphamide — and the CAR–T cells reinfused back into the patient. Cellectis and Juno have fallen behind other CAR-T … |
